Organization Profile

You just read:

Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study

News provided by

Oncolytics Biotech Inc.

Sep 16, 2014, 17:06 ET